We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

LULU:NASDAQlululemon athletica inc. Analysis

Data as of 2026-03-11 - not real-time

$166.43

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Lululemon (LULU) is trading at $166.43, well below its 20‑day SMA of 177.35 and markedly under the 50‑day (188.06) and 200‑day (200.27) averages, indicating a bearish price trend. The RSI of 36.4 suggests momentum is moving out of oversold territory but still weak, while the MACD line sits below its signal line, reinforcing the bearish technical outlook. Volatility remains high at 44% over the past 30 days and beta of 1.22 points to a stock that moves more than the market, amplifying short‑term risk. Fundamentally, the company posts a low trailing P/E of 11.6, a strong ROE of 41%, and a healthy operating margin of 17%, yet the DCF fair value of $134.40 implies the current price is overvalued relative to intrinsic estimates. Recent news highlights the launch of a novel sweat‑concealing technology and heightened investor search interest, but the stock fell 1.96% after guidance that Q4 results would be at the high end of expectations, suggesting market skepticism. The balance sheet shows modest cash of $1.04 bn against $1.76 bn of debt, and free cash flow remains positive, supporting the company’s ability to fund growth initiatives. While the upside/downside metric shows a 24.8% potential upside, this appears driven by historical highs rather than forward fundamentals. Overall, the blend of solid earnings, low valuation multiples, and brand innovation offers a longer‑term investment case, but short‑term price pressure and heightened volatility warrant caution.
Investors should weigh the bearish technical signals and elevated risk metrics against the company’s strong profitability and growth narrative. In the near term, the stock may face further downside pressure, but a medium‑to‑long‑term horizon could capture value as the brand capitalizes on new product launches and global expansion.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Price below all major moving averages
  • Bearish MACD and low RSI
  • High short‑term volatility

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Strong operating margins and ROE
  • Low P/E relative to peers
  • Continued product innovation

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Brand strength and global expansion potential
  • Solid cash flow generation
  • Blend of growth prospects and reasonable valuation

Key Metrics & Analysis

Financial Health

Revenue Growth7.10%
Profit Margin15.72%
P/E Ratio11.6
ROE41.02%
ROA20.29%
Debt/Equity39.16
P/B Ratio4.4
Op. Cash Flow$1.9B
Free Cash Flow$884.9M

Technical Analysis

TrendBearish
RSI36.4
Support$163.45
Resistance$192.49
MA 20$177.35
MA 50$188.06
MA 200$200.27
MACDBearish
VolumeIncreasing
Fear & Greed Index76.91

Valuation

Fair Value$134.40
Target Price$207.70
Upside/Downside24.80%
GradeFair
TypeBlend

Risk Assessment

Beta1.22
Volatility44.04%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.